Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE: BMY) and Tempus AI announced an expanded collaboration using AI, multimodal real-world data, and the Tempus Lens platform to optimize clinical trial design and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial development programs.
The initiative supports solid tumor oncology assets in lung, colon, and prostate cancers and extends into neuroscience for Alzheimer’s disease. It focuses on refining trial assumptions, characterizing complex patient populations, validating control groups, and identifying optimal patient segments for investigational therapies.
Bristol Myers Squibb (NYSE:BMY) is highlighted in a broader look at AI-driven cardiology and novel cardiac therapies. The company reported positive Phase 3 SCOUT-HCM results for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy, meeting the primary endpoint with a -48.0 mm Hg Valsalva LVOT gradient difference vs placebo (P < 0.0001).
No patients experienced left ventricular ejection fraction below 50%. Camzyos is already approved for adult oHCM in over 60 countries and prescribed to more than 22,000 U.S. patients, positioning BMY to potentially seek a pediatric label expansion in a population without targeted therapies.
Bristol Myers Squibb (NYSE:BMY) announced European Commission approval of Sotyktu (deucravacitinib) for adults with active psoriatic arthritis who had inadequate response or intolerance to prior DMARD therapy, effective May 8, 2026. Sotyktu is a once-daily oral TYK2 inhibitor and the first of its class approved in the EU for PsA.
Approval is based on Phase 3 POETYK PsA-1 and PsA-2 trials showing significant improvement on ACR20 (primary) and MDA (key secondary), with QoL gains on SF-36 maintained to Week 52. Safety profile aligns with plaque psoriasis data; warnings include infections, MACE, DVT/PE, malignancies.
Bristol Myers Squibb (NYSE: BMY) will present at the Bank of America Securities Healthcare Conference 2026 on Thursday, May 14, 2026 in a fireside chat starting at 8:40 a.m. PT / 11:40 a.m. ET.
Investors and the public can listen live via the company investor site, with an archived recording available after the session.
Bristol Myers Squibb (NYSE: BMY) launched the “Won’t Lose” media campaign on May 4, 2026, timed ahead of FIFA World Cup 2026™ to spotlight the company’s commitment to advancing breakthrough medicines for patients.
Assets feature narration by Ali Krieger and run across CTV, programmatic display, streaming audio, video and social media; campaign creative and a full transcript are available at www.BMSWontLose.com.
Bristol Myers Squibb (NYSE: BMY) reported first quarter 2026 financial results and provided investor access details. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET on April 30, 2026. A replay will be available about three hours after the call.
Investors can view the detailed earnings press release and presentation on the company’s Investor Relations website and access contact emails for media and investor relations.
Bristol Myers Squibb (BMY) and Pfizer announced that Eliquis (apixaban) will be sold on Mark Cuban Cost Plus Drug Company starting April 27, 2026, offering a 30-day supply for a total cash price of $345. The move expands direct-to-patient access for cash-paying customers alongside the existing Eliquis 360 Support option.
The announcement reiterates Eliquis indications for AFib, DVT/PE, and post-orthopedic surgery, and includes Important Safety Information about bleeding risks and use limitations.
Atrium Therapeutics (Nasdaq: RNA) announced it earned a $15 million development milestone from Bristol Myers Squibb (NYSE: BMY) after delivering a development candidate for a cardiology indication under their global collaboration.
Under the deal Atrium is eligible for up to $1.35 billion in R&D milestones, up to $825 million in commercial milestones, and tiered royalties up to low double-digits; Bristol Myers Squibb will fund future clinical development, regulatory, and commercialization activities.
Foundation Medicine expanded its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne CDx as a next-generation sequencing companion diagnostic to identify patients with homozygous MTAP deletion across multiple indications for an investigational targeted therapy.
FoundationOne CDx is an FDA-approved tissue-based NGS test able to detect copy number loss; the release highlights copy number calling challenges due to low signal-to-noise and emphasizes the test’s ability to report homozygous deletion to help match patients to targeted therapies.
Bristol Myers Squibb (NYSE: BMY) announced an evolution and expansion of its Standing in the Gaap program to advance more equitable multiple myeloma care. The program will launch one of the largest U.S. multiple myeloma surveys, engaging >1,000 patients, caregivers and providers.
The survey, developed with leading advocacy groups, builds on a decade of activity since 2016, including >50 educational programs, ~5,000 attendees and a digital community of nearly 60,000, to translate lived experience into community-informed action.